Pharmaceutical

Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments

The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with fibrostenosing Crohn’s disease.

Oct 26, 2024 - 04:00
Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments
The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with fibrostenosing Crohn’s disease.
Read the original article

Tags:

Previous Article

Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline

Next Article

Dyno and Roche collaborate on neurological gene therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biosyngen’s liver cancer therapy receives fast track designation

Biosyngen’s liver cancer therapy receives fast track de...

Feb 2, 2024

STAT+: Targeted drug greatly slows progression of a brain cancer

STAT+: Targeted drug greatly slows progression of a bra...

Jun 4, 2023

Vertex and Lonza to establish T1D cell therapy manufacturing facility

Vertex and Lonza to establish T1D cell therapy manufact...

Jun 27, 2023